Patient Advocacy at Sage

Putting patients first.

At Sage, our journey of scientific discovery and development is laser-focused on our mission of transforming the lives of people with life-altering CNS disorders. One of our core values is to put people first, which means we are guided every day by the needs and interests of people with CNS disorders, their caregivers and families.

Advocacy

Patient and caregiver perspectives inspire our work—from our study design to our internal culture. Identifying unmet patient needs drives our research and development focus. This patient-centricity keeps everyone grounded in our purpose—to help improve the well-being of patients, caregivers and families impacted by CNS diseases, including Postpartum Depression (PPD) and Major Depressive Disorder.

Postpartum Depression:

  • PPD is one of the most common medical complications during and after pregnancy.1-7

Major Depressive Disorder:

  • Depression is a leading cause of disability worldwide. More than 300 million people worldwide are now living with depression, an increase of 18% between 2005 and 2015.

Feelings of guilt, shame, or fear associated with these disorders can keep sufferers from speaking up and getting care. At Sage, we believe this must change.

Advocacy Partners

We are committed to partnering with the advocacy groups as they strive to reduce suffering and improve quality of life for all who suffer by breaking the stigma associated with mental illness, increasing symptom awareness and diagnosis, and supporting patients in navigating pathways to care.

Our Patient Advocacy team is committed to developing transparent and long-term relationships with advocacy groups that serve the CNS community. These groups are vital, independent patient champions, and we aim to learn from and collaborate with them as we pursue our shared goals.

We hold ourselves accountable for acting with a sense of urgency to help reduce barriers to disease recognition and management. We do this by supporting efforts to:

  • Raise awareness of the burden of CNS disorders
  • Increase early diagnosis and close gaps in care
  • Help patients navigate access to medicines and healthcare services

To learn more about our patient advocacy efforts, email advocacy@sagerx.com

References

  1. Ko JY et al. MMWR Morb Mortal Wkly Rep. 2017;66:153-158.
  2. Hamilton BE et al; National Center for Health Statistics. Births: Provisional data for 2018. Vital Statistics Rapid Release; no 7. https://www.cdc.gov/nchs/data/vsrr/vsrr-007-508.pdf. Published May 2019. Accessed July 9, 2019.
  3. DeSisto CL et al. Prev Chronic Dis. 2014;11:E10.
  4. Centers for Disease Control and Prevention. https://www.cdc.gov/reproductivehealth/maternalinfanthealth/diabetes-during-pregnancy.htm. Updated June 12, 2018. Accessed July 9, 2019.
  5. Centers for Disease Control and Prevention. https://www.cdc.gov/reproductivehealth/maternalinfanthealth/pregnancy-complications-data.htm. Updated February 28, 2019. Accessed July 15, 2019.
  6. Roberts JM et al; American College of Obstetricians and Gynecologists Task Force on Hypertension in Pregnancy. https://www.acog.org/~/media/Task%20Force%20and%20Work%20Group%20Reports/public/HypertensioninPregnancy.pdf. Published 2013. Accessed July 9, 2019.
  7. Callaghan WM et al. Am J Obstet Gynecol. 2010;202(4):353.e1-6.